Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

NCT03957551 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

28

Enrollment

OTHER

Sponsor class

Stopped Study was terminated early due to changes in the treatment of melanoma

Conditions

Advanced Metastatic Melanoma

Interventions

DRUG: Cabozantinib
DRUG: Pembrolizumab

Sponsor

John Rieth

Collaborators

[object Object]
[object Object]